Laquinimod

Source: Wikipedia, the free encyclopedia.
Laquinimod
Names
Preferred IUPAC name
5-Chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
Identifiers
3D model (
JSmol
)
ChEMBL
ChemSpider
ECHA InfoCard
 100.220.145 Edit this at Wikidata
IUPHAR/BPS
UNII
  • InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3 checkY
    Key: GKWPCEFFIHSJOE-UHFFFAOYSA-N checkY
  • InChI=1/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3
    Key: GKWPCEFFIHSJOE-UHFFFAOYAW
  • CCN(c1ccccc1)C(=O)C\3=C(/O)c2c(Cl)cccc2N(C)C/3=O
Properties
C19H17ClN2O3
Molar mass 356.803 g/mol
Pharmacology
N07XX10 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Laquinimod is an experimental

Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease
.

Laquinimod is the successor of Active Biotech's failed experimental immunomodulator

linomide.[1]

The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.[2][3][4] However, the response to a given dose was discrepant between both studies.[5]

Phase III studies for MS started in December 2007.[6] In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in MS among patients beyond a placebo.[7] However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.[8][clarification needed]

On May 7, 2013 laquinimod was approved by the Russian Ministry of Health (the FDA analog) as a treatment for relapsing-remitting multiple sclerosis (RRMS) under the brand name Nerventra.[9]

See also

References

  1. PMID 10773855
    .
  2. PMID 18572078
    .
  3. PMID 15781813
    .
  4. PMID 23922214
    .
  5. PMID 18572062
    .
  6. ^ Clinical trial number NCT00509145 for "Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)" at ClinicalTrials.gov
  7. ^ Kresege, Naomi (1 August 2011). "Teva's Copaxone Successor Fails in Latest Clinical Trial". Bloomberg. Retrieved 2 August 2011. Teva Pharmaceutical Industries Ltd. (TEVA)'s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company's effort to find a successor to an older drug.
  8. PMID 22417253
    .
  9. ^ "Nerventra (laquinimod) Capsules 0,6 mg. Registration certificate". State Register of Medicines (in Russian). Retrieved 21 October 2015.

External links



drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Laquinimod&oldid=1198908214"